Gelmedix
GelMEDIX is a pre-clinical biotech developing an injectable hydrogel scaffold platform to improve cell and gene therapy delivery, with lead program GMX-101 (iPSC-derived RPE cell therapy) targeting late-stage Geographic Atrophy.
- Company typePrivate
- Founded2020
- HeadquartersNewton, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Gelmedix does
GelMEDIX is a privately held, pre-clinical biotechnology company founded in 2020 and headquartered in Cambridge, Massachusetts. The company is developing regenerative vision therapies built on a proprietary injectable hydrogel scaffold platform designed to protect therapeutic cells during injection, localize them to target tissues, and promote tissue regeneration while degrading naturally as new tissue forms. The technology is engineered to address core failure modes in cell and gene therapy delivery — specifically poor cell survival and engraftment — by providing a regenerative scaffold that integrates with newly formed tissue at the disease site.
The company's lead program, GMX-101, combines iPSC-derived retinal pigment epithelial (RPE) cells with the hydrogel scaffold to restore vision in patients with late-stage Geographic Atrophy (GA), a progressive form of dry age-related macular degeneration causing irreversible central vision loss in adults over 60. GelMEDIX is also positioning the hydrogel scaffold as a licensable delivery platform for stem cell-derived therapies developed by external pharmaceutical partners, with stated ambitions to extend beyond ophthalmology into other degenerative disorders. Preclinical efficacy in RPE cell transplantation has been demonstrated in ARVO Annual Meeting presentations across 2023, 2024, and 2025.
GelMEDIX operates a B2B, partnership-driven business model and does not yet have commercialized products. Future revenue is expected to flow from licensing and milestone payments under pharmaceutical partnerships, contract development and manufacturing arrangements, and ultimately from commercialization of proprietary cell therapies such as GMX-101. The company has raised approximately $13 million in a seed financing round led by Safar Partners (closed February 2026), with prior equity from HTL Biotechnology (2022), a $3.5M exempt offering (2024), and angel groups. Strategic partnerships with a global pharmaceutical company (February 2026) and Catalent (March 2026) anchor the commercial development pathway.
Gelmedix firmographics
Firmographics- Name
- Gelmedix
- Legal name
- GelMEDIX, Inc.
- Website
- https://gelmedix.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- GelMEDIX is a pre-clinical biotech developing an injectable hydrogel scaffold platform to improve cell and gene therapy delivery, with lead program GMX-101 (iPSC-derived RPE cell therapy) targeting late-stage Geographic Atrophy.
- Ownership category
- akta.pro rank
Gelmedix industry classification
Industry- Product category
- Ophthalmic Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)
Keywords
Where Gelmedix is headquartered
LocationHeadquarters
- HQ city
- Newton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Gelmedix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Others
Revenue model
- Strategic Partnerships and Licensing: GelMEDIX generates revenue through licensing its proprietary hydrogel scaffold technology to pharmaceutical partners, including milestone payments and potential future revenue streams. The company announced its first strategic collaboration with a global pharmaceutical company involving supplying hydrogel technology for use with the partner's stem cell-derived cell lines.
- Contract Development and Manufacturing: Partnership with Catalent for development and clinical manufacturing of iPSC-derived cell therapies. While this is primarily for advancing GelMEDIX's own pipeline, it establishes manufacturing capabilities that could support future commercial partnerships.
- Pipeline Development and Milestones: Advancing lead program GMX-101 through clinical development. Potential revenue from achieving development milestones, regulatory approvals, and commercialization of proprietary cell therapies.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Gelmedix product offering
Product offeringCore offering
GelMEDIX is a pre-clinical biotechnology company developing a proprietary injectable hydrogel scaffold platform engineered to improve the functional replacement and integration of therapeutic cells and the delivery of gene therapies. The platform protects cells during injection, localizes them to target sites, and provides a regenerative structure that degrades naturally over time as new tissue forms. Its lead program, GMX-101, combines iPSC-derived retinal pigment epithelial (RPE) cells with the hydrogel technology to restore vision in late-stage Geographic Atrophy patients.
Product overview
GelMEDIX is a biotechnology company developing regenerative vision therapies based on a proprietary injectable hydrogel scaffold platform. The platform is designed to optimize the delivery, efficacy, and safety of cell and gene therapies. The company's lead product is GMX-101, an iPSC-derived RPE cell therapy for late-stage Geographic Atrophy, which combines the hydrogel scaffold with therapeutic cells to restore vision. The company is building a pipeline of next-generation therapies for degenerative eye diseases and forging strategic partnerships to advance cell and gene therapies for other degenerative disorders.
Differentiator
Problem solved
Functional benefit
Products and services
- GMX-101 RPE Cell Therapy
Quantifiable outcome
- GMX-101 demonstrated significant vision preservation in preclinical studies while eliminating risks associated with other RPE cell therapies
Companies that use Gelmedix
Customer profileSegments3 records
Ideal customer profiles2 records
Gelmedix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Gelmedix partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship.
- CatalentflagshipGlobal partnership for development and clinical manufacturing of iPSC-derived cell therapies targeting ocular and retinal diseases. Catalent provides GMP-compliant induced pluripotent stem cell lines and manufacturing capabilities, including process development, analytical development, process scale-up, and GMP manufacturing support through all clinical stages. The partnership is designed to accelerate GelMEDIX's progress toward clinical trials.
- Global Pharmaceutical Company (Unnamed)flagshipGelMEDIX announced its first strategic collaboration with a global pharmaceutical company to leverage GelMEDIX's injectable hydrogel scaffold technology for developing stem cell-derived cell therapies. The partnership involves supplying GelMEDIX's hydrogel technology for use with the partner's stem cell-derived cell lines, creating potential future revenue and milestone streams.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Gelmedix competitors and assessment
Company assessmentOthers
- Catalent: Existing CDMO partner of GelMEDIX and one of the largest cell therapy contract manufacturers; relevant as a strategic enabler of GelMEDIX's manufacturing pathway and an indicator of CDMO-led cell therapy trends.
Broad incumbents
- REGENXBIO: AAV gene therapy platform with ophthalmology and rare disease programs (ABBV-RGX-314 for wet AMD/diabetic retinopathy); a broader gene therapy delivery company relevant to the gene therapy half of GelMEDIX's platform thesis.
- Regeneron Pharmaceuticals: Markets Eylea, the dominant anti-VEGF therapy for retinal diseases including wet AMD; a large incumbent shaping the retinal therapeutics market that any new entrant must compete against or partner with.
Direct peers
- Adverum Biotechnologies: Develops intravitreal gene therapies for wet AMD and other ocular diseases; comparable as an ocular-delivery-focused platform company working on retinal therapeutics.
- Lineage Cell Therapeutics: Develops OpRegen, an allogeneic RPE cell therapy for dry AMD/geographic atrophy; the most direct clinical-stage peer competing in the same indication with a similar cell-replacement approach.
- Apellis Pharmaceuticals: Markets Syfovre, the first FDA-approved treatment for geographic atrophy; defines the current standard of care that any late-stage GA therapy must differentiate against.
- Astellas Pharma (Iveric Bio): Acquired Iveric Bio for Izervay, another approved GA therapy, and has historically pursued RPE regenerative approaches (notably via the Ocata acquisition); a key competitor and potential strategic acquirer in the GA space.
- BlueRock Therapeutics: Bayer-owned pluripotent stem cell therapy developer with programs in ophthalmology (RP) and other regenerative indications; directly comparable as a cell-therapy platform company advancing iPSC-derived therapeutics into the clinic.
- Eyevensys: Clinical-stage biotech developing non-viral gene therapies for ophthalmic diseases using a proprietary electro-transfection delivery platform; comparable as an ocular therapeutics delivery-focused company.
Emerging players
- ViaCyte: Pioneer in stem cell-derived cell therapies (now part of Vertex) with deep expertise in iPSC manufacturing and engraftment; comparable as a platform cell-therapy peer with shared delivery/encapsulation challenges.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks1 record
Key highlights6 records
Customer concentration
Gelmedix social profiles
Digital presenceGelmedix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gelmedix leadership team
Management profileNumber of profiles
Profiles10 records
Gelmedix funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gelmedix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gelmedix
What does Gelmedix do?
GelMEDIX is a pre-clinical biotechnology company developing a proprietary injectable hydrogel scaffold platform engineered to improve the functional replacement and integration of therapeutic cells and the delivery of gene therapies. The platform protects cells during injection, localizes them to target sites, and provides a regenerative structure that degrades naturally over time as new tissue forms. Its lead program, GMX-101, combines iPSC-derived retinal pigment epithelial (RPE) cells with the hydrogel technology to restore vision in late-stage Geographic Atrophy patients.
Is Gelmedix a public or private company?
Gelmedix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Gelmedix founded?
Gelmedix was founded in 2020. It employs 1 to 10 people.
Where is Gelmedix based?
Gelmedix is headquartered in Newton, United States, in the North America region.
How does Gelmedix make money?
Three revenue lines are on record. Strategic Partnerships and Licensing is the primary driver. The others are contract Development and Manufacturing and pipeline Development and Milestones.
Who are Gelmedix's main competitors?
Catalent is listed as an others. Broad incumbents are REGENXBIO and Regeneron Pharmaceuticals. Direct peers are Adverum Biotechnologies, Lineage Cell Therapeutics, Apellis Pharmaceuticals, Astellas Pharma (Iveric Bio), BlueRock Therapeutics and Eyevensys. ViaCyte is listed as an emerging player.
Does Gelmedix have an API?
No public API is recorded for Gelmedix.
What industry is Gelmedix in?
Gelmedix's product category is Ophthalmic Biologics. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.